Pediatric Neurology
Volume 26, Issue 3 , Pages 181-185 , March 2002

Pyridoxine-dependent seizures: findings from recent studies pose new questions

  • Sidney M Gospe Jr, MD, PhD

      Affiliations

    • Corresponding Author InformationCommunications should be addressed to: Dr. Gospe; Children’s Hospital and Regional Medical Center; 4800 Sand Point Way NE, Neurology; CH-49, Seattle, WA 98105 USA
    • Division of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Washington, and Children’s Hospital and Regional Medical Center, Seattle, WA 98105, USA

Received 2 May 2001 ,Accepted 4 October 2001.

References 

  1. Hunt AD, Stokes J, McCrory WW, Stroud HH. Pyridoxine dependency (Report of a case of intractable convulsions in an infant controlled by pyridoxine). Pediatrics. 1954;13:140–145
  2. Baxter P. Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. Arch Dis Child. 1999;81:431–433
  3. Gordon N. Pyridoxine dependency (An update). Dev Med Child Neurol. 1997;39:63–65
  4. Gospe SM. Current perspectives on pyridoxine-dependent seizures. J Pediatr. 1998;132:919–923
  5. Haenggeli C-A, Girardin E, Paunier L. Pyridoxine-dependent seizures, clinical and therapeutic aspects. Eur J Pediatr. 1991;150:452–455
  6. Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. Dev Med Child Neurol. 2001;43:416–420
  7. Bankier A, Turner M, Hopkins IJ. Pyridoxine dependent seizures—a wider clinical spectrum. Arch Dis Child. 1983;58:415–418
  8. Goutières F, Aicardi J. Atypical presentations of pyridoxine-dependent seizures (A treatable cause of intractable epilepsy in infants). Ann Neurol. 1985;17:117–120
  9. Clarke TA, Saunders BS. Pyridoxine-dependent seizures requiring high doses of pyridoxine for control. Am J Dis Child. 1979;133:963–965
  10. Coker S. Postneonatal vitamin B6-dependent epilepsy. Pediatrics. 1992;90:221–223
  11. Chou ML, Wang HS, Hung PC, Sun PC, Huang SC. Late-onset pyridoxine-dependent seizures (Report of two cases). Acta Paediatr Sin. 1995;36:434–437
  12. Bass NE, Wyllie E, Cohen B, Joseph SA. Pyridoxine-dependent epilepsy (The need for repeated pyridoxine trials and the risk of severe electrocerebral suppression with intravenous pyridoxine infusion). J Child Neurol. 1996;11:422–424
  13. Grillo E, da Silva EJM, Barbata JH. Pyridoxine-dependent seizures responding to extremely low-dose pyridoxine. Dev Med Child Neurol. 2001;43:413–415
  14. Battaglioli G, Rosen DR, Gospe SM, Martin DL. Glutamate decarboxylase is not genetically linked to pyridoxine-dependent seizures. Neurology. 2000;55:309–311
  15. Cormier-Daire V, Dagoneau N, Nabbout R, et al.  A gene for pyridoxine-dependent epilepsy maps to chromosome 5q31. Am J Hum Genet. 2000;67:991–993
  16. Kure S, Sakata J, Miyabayshi S, et al.  Mutation and polymorphic marker analyses of 65K- and 67K-glutamate decarboxylase genes in two families with pyridoxine-dependent epilepsy. J Hum Genet. 1998;43:128–131
  17. Baumeister FAM, Gsell W, Shin YS, Egger J. Glutamate in pyridoxine-dependent epilepsy (Neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine). Pediatrics. 1994;94:318–321
  18. Gospe SM, Olin KL, Keen CL. Reduced GABA synthesis in pyridoxine-dependent seizures. Lancet. 1994;343:1133–1134
  19. Kurlemann G, Menges EM, Palm DG. Low level of GABA in CSF in vitamin B6-dependent seizures. Dev Med Child Neurol. 1991;33:749–750
  20. Kurlemann G, Ziegler R, Gruneberg M, Bomelburg T, Ullrich K, Palm DB. Disturbance of GABA metabolism in pyridoxine-dependent seizures. Neuropediatrics. 1992;23:257–259
  21. Kure S, Maeda T, Fukushima N, et al.  A subtype of pyridoxine-dependent epilepsy with normal CSF glutamate concentration. J Inherit Metab Dis. 1998;21:431–432
  22. Baxter P, Griffiths P, Kelly T, Gardner-Medwin D. Pyridoxine-dependent seizures (Demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient). Dev Med Child Neurol. 1996;38:998–1006
  23. Shih JJ, Kornblum H, Shewmon DA. Global brain dysfunction in an infant with pyridoxine dependency (Evaluation with EEG, evoked potentials, MRI, and PET). Neurology. 1996;47:824–826
  24. Tanaka R, Okumura M, Arima J, Yamakura S, Momoi T. Pyridoxine-dependent seizures (Report of a case with atypical clinical features and abnormal MRI scans). J Child Neurol. 1992;7:24–28
  25. Jardin LB, Pires RF, Martins CES, et al.  Pyridoxine-dependent seizures associated with white matter abnormalities. Neuropediatrics. 1994;25:259–261
  26. Gospe SM, Hecht ST. Longitudinal MRI findings in pyridoxine-dependent seizures. Neurology. 1998;51:74–78
  27. Mikati MA, Trevathan E, Krishnamoorthy KS. Pyridoxine-dependent epilepsy (EEG investigation and long-term follow-up). Electroencephalogr Clin Neurophysiol. 1991;78:215–221
  28. Nabbout R, Soufflet C, Plouin P, Dulac O. Pyridoxine dependent epilepsy (A suggestive electroclinical pattern). Arch Dis Child Fetal Neonatal Educ. 1999;81:F125–F129
  29. Bejšovec M, Kulenda Z, Ponca E. Familial intrauterine convulsions in pyridoxine dependency. Arch Dis Child. 1967;42:201–207
  30. Kroll JS. Pyridoxine for neonatal seizures (An unexpected danger). Dev Med Child Neurol. 1985;27:369–382
  31. Ito M, Okuno T, Hattori H, Fujii T, Mikawa H. Vitamin B6 and valproic acid in treatment of infantile spasms. Pediatr Neurol. 1991;7:91–96
  32. Pietz J, Benninger C, Schafer H, Sontheimer D, Mittermaier G, Rating D. Treatment of infantile spasms with high-dosage vitamin B6. Epilepsia. 1993;34:757–763
  33. Ohtsuka Y, Ogino T, Asano T, Hattori J, Ohta H, Oka E. Long-term follow-up of vitamin B6-responsive West syndrome. Pediatr Neurol. 2000;23:202–206
  34. Takuma Y. ACTH therapy for infantile spasms (A combination therapy with high-dose pyridoxal phosphate and low-dose ACTH). Epilepsia. 1998;39(Suppl 5):42–45
  35. Jiao FY, Gao DY, Takuma Y, et al.  Randomized, controlled trial of high-dose intravenous pyridoxine in the treatment of recurrent seizures in children. Pediatr Neurol. 1997;17:54–57
  36. Hansson O, Hagberg B. Effect of pyridoxine treatment in children with epilepsy. Acta Soc Med Ups. 1968;73:35–43
  37. Burd L, Stenehjem A, Franceschini LA, Kerbeshian J. A 15-year follow-up of a boy with pyridoxine (vitamin B6)-dependent seizures with autism, breath holding, and severe mental retardation. J Child Neurol. 2000;15:763–765
  38. McLachlan RS, Brown WF. Pyridoxine dependent epilepsy with iatrogenic sensory neuronopathy. Can J Neurol Sci. 1995;22:50–51
  39. Ohtsuka Y, Hattori J, Ishida T, Ogino T, Oka E. Long-term follow-up of an individual with vitamin B6-dependent seizures. Dev Med Child Neurol. 1999;41:203–206
  40. Baxter P, Aicardi J. Neonatal seizures after pyridoxine use. [letter] Lancet. 1999;354:2082–2083
  41. Scriver CR. Vitamin B6-dependency and infantile convulsions. Pediatrics. 1960;26:62–74
  42. Lott IT, Coulombe T, Di Paolo RV, Richardson EP, Levy HL. Vitamin B6-dependent seizures (Pathology and chemical findings in brain). Neurology. 1978;28:47–54
  43. Goto T, Matsuo N, Takahashi T. CSF glutamate/GABA concentrations in pyridoxine-dependent seizures (Etiology of pyridoxine-dependent seizures and the mechanisms of pyridoxine action in seizure control). Brain Dev. 2001;23:24–29
  44. Kurlemann G, Deufel T, Schuierer G. Pyridoxine-responsive West syndrome and gamma-aminobutyric acid. Eur J Pediatr. 1997;156:158–159
  45. Bendich A, Cohen M. Vitamin B6 safety issues. Ann NY Acad Sci. 1990;585:321–330
  46. Kouyoumdjian JC, Ebadi J. Anticonvulsant activity of muscimol and gamma-aminobutyric acid against pyridoxal phosphate-induced seizures. J Neurochem. 1981;36:251–257
  47. Verešová S, Kábová R, Velı́šek L. Proconvulsant effects induced by pyridoxine in young rats. Epilepsy Res. 1998;29:259–264
  48. Hammen A, Wagner B, Berkhoff M, Donati F. A paradoxical rise of neonatal seizures after treatment with vitamin B6. Eur J Paediatr Neurol. 1998;2:319–322
  49. Kaufman KJ, Lederman JN, Wong AM, Tobin AJ, Menkes JH. A new method to detect point mutations in the gene for glutamic acid decarboxylase in patients with pyridoxine-dependent seizures. [abstract] Ann Neurol. 1987;22:446–447
  50. Plecko B, Stöckler-Ipsiroglu S, Paschke E, Erwa W, Struys EA, Jakobs C. Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy. Ann Neurol. 2000;48:121–125
  51. Gutierrez MC, Delgado-Coello BA. Influence of pipecolic acid on the release and uptake of [3H]-GABA from brain slices of mouse cerebral cortex. Neurochem Res. 1989;14:405–408
  52. Diaz GA, Banikazemi M, Oishi K, Desnick RJ, Gelb BD. Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet. 1999;22:309–312
  53. Fleming JC, Tartaglini E, Steinkamp MP, Schorderet DF, Cohen N, Neufeld EJ. The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nat Genet. 1999;22:305–308
  54. Gong M, Yess J, Connolly T, Ivy SP, Ohnuma T, Cowan KH, et al. Molecular mechanisms of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Blood. 1997;87:2494–2499
  55. Kobayashi H, Takemura Y, Ohnuma T. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates. Cancer Lett. 1998;124:135–142
  56. Shin YS, Rasshofer R, Endres W. Pyridoxal-5′-phosphate concentration as marker for vitamin-B6-dependent seizures in the newborn. [letter] Lancet. 1984;2(8407):870–871

PII: S0887-8994(01)00407-6

Pediatric Neurology
Volume 26, Issue 3 , Pages 181-185 , March 2002

Article Tools